BLI800 + Fortrans®
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diagnosis Disease
Conditions
Diagnosis Disease
Trial Timeline
Jul 1, 2018 → Apr 28, 2019
NCT ID
NCT03562884About BLI800 + Fortrans®
BLI800 + Fortrans® is a phase 3 stage product being developed by Ipsen for Diagnosis Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03562884. Target conditions include Diagnosis Disease.
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03562884 | Phase 3 | Completed |
Competing Products
5 competing products in Diagnosis Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pemetrexed + Erlotinib + Pemetrexed + Erlotinib | Eli Lilly | Phase 2 | 35 |
| ABT-414 | AbbVie | Pre-clinical | 26 |
| Pembrolizumab + Irinotecan + Paclitaxel | Merck | Phase 2 | 35 |
| rHuPH20 + zoledronic acid | Halozyme Therapeutics | Phase 1 | 26 |
| 18F- DCFPyl Injection | Lantheus Holdings | Phase 2 | 39 |